Related Experiment Video
Updated: Aug 14, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
p53 enhances the Delta-24 conditionally replicative adenovirus anti-glioma effect
P G Mitlianga1, C Sioka, G Vartholomatos
1NeuroSurgical Institute, University of Ioannina, Greece. pmitliag@cc.uoi.gr
Abstract:
Previous studies have demonstrated that the conditionally replicative adenovirus Ad5Delta24 is a powerful cytolytic agent against glioma selectively affecting cells with a defective p16/Rb/E2F pathway. The p53 protein is also known to be an apoptotic factor for glioma cells. In this study, we examined the simultaneous delivery of the combination of exogenous p53 and Ad5Delta24 adenovirus in glioma cells. Infecting cells with low doses of adenovirus p53 and Ad5Delta24 resulted in an additive effect on cell death. The cell death induced by both agents was independent of the p53 status of cells. Flow cytometry revealed that the potent anti-tumor effect induced by the mixture of Ad5CMV-p53 and Ad5Delta24 adenoviruses was due to a combination of apoptosis and cell lysis. Our results indicate that Ad5CMV-p53 enhances the oncolytic effect of the Ad5Delta24 adenovirus, and the combination of adenovirus Ad5Delta24 and Ad5CMV-p53 may thus be a potential therapeutic tool for gliomas.
Insights
Combining Ad5Delta24 adenovirus with p53 gene therapy shows enhanced cell death in glioma cells. This dual approach, targeting the p16/Rb/E2F pathway and apoptosis, offers a promising new strategy for glioma treatment.
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- Glioma is a challenging brain tumor with limited treatment options.
- The conditionally replicative adenovirus Ad5Delta24 selectively targets glioma cells with defective p16/Rb/E2F pathways.
- The p53 protein acts as an apoptotic factor in glioma cells.
Purpose of the Study:
- To investigate the combined therapeutic effect of Ad5Delta24 adenovirus and exogenous p53 delivery in glioma cells.
- To determine if simultaneous administration enhances anti-tumor activity.
Main Methods:
- Glioma cells were infected with low doses of Ad5CMV-p53 and Ad5Delta24 adenoviruses.
- Cell death was assessed using flow cytometry.
- The mechanism of cell death (apoptosis and lysis) was analyzed.
Main Results:
- The combination of Ad5CMV-p53 and Ad5Delta24 induced an additive effect on glioma cell death.
- The enhanced cell death was independent of the cells' p53 status.
- Flow cytometry confirmed that the anti-tumor effect resulted from a combination of apoptosis and cell lysis.
Conclusions:
- Ad5CMV-p53 significantly enhances the oncolytic effect of Ad5Delta24 adenovirus.
- The combination of Ad5Delta24 and Ad5CMV-p53 represents a potential therapeutic strategy for treating gliomas.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle

